References
  1. Allanson, JE, Roberts AE. Noonan syndrome. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK1124/ 2019, August 8.
  2. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome.Lancet. 2013; 381: 333-42.
  3. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics.2010; 126: 746-59.
  4. Noonan JA, Ehmke DA. Associated noncardiac malformations in children with congenital heart disease. Midwest Soc Pediatr Res. 1963; 63: 468-70.
  5. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet.1985; 21: 493-506.
  6. Tartaglia M, Gelb BD. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet. 2005; 48: 81-96.
  7. Jongmans MC, van der Burgt I, Hoogerbrugge PM, et al. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet. 2011; 19: 870-4.
  8. Han T, Xiang DM, Sun W, et al. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.J Hepatol. 2015; 63: 651-60.
  9. Bard-Chapeau EA, Li S, Ding J, et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell. 2011; 19: 629-39.
  10. Jiang C, Hu F, Tai Y, et al. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2012; 138:637-46.
  11. Grossmann KS, Rosário M, Birchmeier C, et al. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res. 2010; 106: 53-89.
  12. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004; 103: 2325-31.
  13. Kogiso T, Tokushige K. Fontan-associated liver disease and hepatocellular carcinoma in adults. Sci Rep. 2020; 10: 21742.